When it comes to probiotics, consumers must be aware that more is not better. Some brands use vast amounts of bacteria because they have no way of ensuring that the bacteria can remain 'alive' or viable in the gastrointestinal tract. They have more hope that at least some bacteria will reach the large intestine, where they are most needed. The truth is that the viability and effect of probiotics can only be ascertained through a scientific approach. A lot of products come with high numbers, but in reality, users get much less as the bacteria are damaged during production or storage. They end up paying for what's on the label, rather than the product.
ProBion is at the forefront of probiotics and human health. A proprietary low-compression ProBion Matrix technique - which is based on skill and experience - allows the survival of these bacterial colonies.
As a result of this time disintegration and targeted bacteria release effect, the majority of probiotic colonies are not exposed to the hazards of bile and gastric acids. By the time of their release, they have reached their desired destination in the gut and bypassed the danger zones.
This is one of the main reasons why DuPont and Sweden's Sahlgrenska Academy have decided to use ProBion Clinica for their innovative clinical study involving colon cancer patients, which was published by BMJ Open Gastroenterology in July last year.
Developed by Wasa Medicals in Sweden, ProBion was used in a 2017 double-blind clinical study of a probiotic intervention in colon cancer patients. The research showed that taking two ProBion Clinica tablets daily for an average of 31 days (range 8-78 days) wiped out a significant amount of cancer-associated harmful bacteria and generated a plethora of beneficial bacteria with anti-inflammatory effects. ProBion tablets delivered undamaged bacteria to the gut while promoting the growth of beneficial bacteria.
ProBion has the viability, bacterial integrity and quality assurance needed for clinical trials.